Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2

OBJECTIVES: Favipiravir has discrepant activity against SARS-CoV-2 in vitro, concerns about teratogenicity and pill burden, and an unknown optimal dose. This analysis used available data to simulate the intracellular pharmacokinetics of the favipiravir active metabolite [favipiravir ribofuranosyl-5′...

Descripción completa

Detalles Bibliográficos
Autores principales: Pertinez, Henry, Rajoli, Rajith K R, Khoo, Saye H, Owen, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194902/
https://www.ncbi.nlm.nih.gov/pubmed/34075418
http://dx.doi.org/10.1093/jac/dkab135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194902/
https://www.ncbi.nlm.nih.gov/pubmed/34075418
http://dx.doi.org/10.1093/jac/dkab135

Ejemplares similares